Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease.
about
Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary diseaseTiotropium for stable chronic obstructive pulmonary diseaseAnticholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary diseaseLong-lasting target binding and rebinding as mechanisms to prolong in vivo drug actionPharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPDTiotropium in asthma: what is the evidence and how does it fit in?The evidence on tiotropium bromide in asthma: from the rationale to the bedside.Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetineCrosstalk between beta-2-adrenoceptor and muscarinic acetylcholine receptors in the airwayTiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease.Tiotropium bromide.Muscarinic receptor signaling in the pathophysiology of asthma and COPD.Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD.Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switchA randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.Chronic obstructive pulmonary disease * 12: New treatments for COPDUnderdiagnosed asthma in South Australia.Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease.Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDTiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease.Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroidsThe role of tiotropium in the management of asthma.Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis.Tiotropium: a bronchodilator for chronic obstructive pulmonary disease.Muscarinic receptors and their antagonists in COPD: anti-inflammatory and antiremodeling effects.SR2067 Reveals a Unique Kinetic and Structural Signature for PPARγ Partial Agonism.Effect of add-on therapy of tiotropium in COPD treated with theophylline.Tiotropium Attenuates Virus-Induced Pulmonary Inflammation in Cigarette Smoke-Exposed Mice.The development of anticholinergics in the management of COPD.Optimizing bronchodilator therapy in emphysema.Similarities and differences in the autonomic control of airway and urinary bladder smooth muscleThe combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease.Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes.Safety and pharmacological profile of tiotropium bromide.Early intervention with tiotropium in Chinese patients with GOLD stages I-II chronic obstructive pulmonary disease (Tie-COPD): study protocol for a multicentre, double-blinded, randomised, controlled trial.Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years.The cardiovascular risk of tiotropium: is it real?NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease.
P2860
Q24245413-9DA8588F-6E1E-49C6-A126-C190AA46FA06Q24246991-8CBDFD5B-7AB0-4E9E-8EA3-F6DE12E801B0Q24250271-C6939C6A-9925-494B-A133-61B8BEF76E38Q24595639-D5EEDC84-32D1-4A4A-B7B6-293679CDB778Q26778685-03BFC326-F4A6-4D6C-B302-10963B55113AQ28067912-D81A8724-DD9E-442A-9A70-6E2D0076B754Q33644971-6C607444-7F58-4A10-8294-DF42B02594A2Q33870452-A137378D-A2B4-4822-AC26-C40FFD9020E2Q33896990-CE408BD9-98C4-4DB9-9269-D91F0D6318B3Q34177358-2EB6AC96-C434-46F0-A355-CE2FBDEC3993Q34204383-993BE60C-89BF-489E-A5C8-15EECD8E366AQ34684230-F6FECB19-978A-43AF-B161-924FE4E3132BQ34903093-4B7B0523-7BEE-4FBC-B044-2944F14631A7Q34944616-982F3ADB-401B-4B96-BAD0-274A74177817Q35092135-EAE8657D-AD52-49C1-940B-B0096F3B4C9DQ35208742-B674B932-D149-4368-A864-3F2811072E8FQ35535482-A9D409D2-747E-433B-B92B-0C4599943AA3Q35535487-B9918A4F-F422-4EA5-BAEB-367068CEBC94Q35535912-253590E7-A10A-4584-8D7D-ECAE92AD94CBQ35841607-63F9221F-C565-417F-BB40-AFD17FA64011Q35876509-89345156-7FBF-4382-BBB7-6EC1DB730A34Q35937096-4E59FCCD-FDB8-41BF-AA0A-CA76BF025943Q36184259-D05D03D5-89EA-4FB2-A221-9B7443B308EFQ36200675-FEE35273-FD5D-4049-B733-29637B8A5499Q36440308-0B9AB096-82A5-4638-941B-00CD85FDC938Q36760160-62AE6B39-2CE8-499C-96D5-54A8ADDAC553Q36859441-B2358C2F-D7B8-4E45-B975-FC46C38957D4Q36947774-FBC4E3CB-8B9A-4E39-A5EC-806602155F4BQ37017248-5AF8E38B-C775-4361-BD29-C37C064132B7Q37153289-13964BAA-86DB-4B3B-8296-A04A206FF6C5Q37189382-FD2F737B-9364-4ABB-B940-499674563B98Q37221196-8BA167FE-DF53-4797-BC31-A31A1AB03340Q37284889-97FF35C8-598F-4C2B-9E9D-25C5C82D9D2DQ37510963-C032D458-EA1E-4DDA-B8F3-6E217649705FQ37598054-BFCBA4CC-C764-4F35-838F-EC96A95BDAD9Q37698624-296F1903-9E72-4D94-BD9A-6F6BF854F74CQ37766601-E93D28C4-C032-4726-AD47-9EA052CEB0CDQ37867838-2C656C63-A169-4A68-97EC-E4A96B061EE3Q37895710-2F4F3643-ED6A-4606-BABF-3537FB128666Q37937549-CBA12DE9-28DD-48E1-88D3-C9D8AFD4558F
P2860
Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Tiotropium (Spiriva): mechanis ...... e in obstructive lung disease.
@ast
Tiotropium (Spiriva): mechanis ...... e in obstructive lung disease.
@en
Tiotropium
@nl
type
label
Tiotropium (Spiriva): mechanis ...... e in obstructive lung disease.
@ast
Tiotropium (Spiriva): mechanis ...... e in obstructive lung disease.
@en
Tiotropium
@nl
prefLabel
Tiotropium (Spiriva): mechanis ...... e in obstructive lung disease.
@ast
Tiotropium (Spiriva): mechanis ...... e in obstructive lung disease.
@en
Tiotropium
@nl
P2093
P1433
P1476
Tiotropium (Spiriva): mechanis ...... e in obstructive lung disease.
@en
P2093
P304
P356
10.1016/S0024-3205(98)00588-8
P407
P577
1999-01-01T00:00:00Z